Astellas buys UK group Quethera
Astellas has acquired Cambridge, UK-based Quethera, a gene therapy group focused on the development of novel treatments for ocular disorders, such as glaucoma.
Read More
Tag: Quethera
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
- CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
